scholarly journals Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON‐PFT Extension I Trials

2019 ◽  
Vol 34 (5) ◽  
pp. 810-816 ◽  
Author(s):  
Tiffany Y Kim ◽  
Douglas C Bauer ◽  
Brian L McNabb ◽  
Anne L Schafer ◽  
Felicia Cosman ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Formation Marker

scholarly journals Serum bone formation marker correlation with improved osseointegration in osteoporotic rats treated with simvastatin

2011 ◽  
Vol 24 (4) ◽  
pp. 422-427 ◽  
Author(s):  
Zhibin Du ◽  
Jiang Chen ◽  
Fuhua Yan ◽  
Nghiem Doan ◽  
Saso Ivanovski ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Formation Marker

Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate

2013 ◽  
Vol 91 (5) ◽  
pp. 380-385 ◽  
Author(s):  
Hoda Derakhshanian ◽  
Mahmoud Djalali ◽  
Abolghassem Djazayery ◽  
Keramat Nourijelyani ◽  
Sajad Ghadbeigi ◽  
...  
Keyword(s):  
Bone Formation ◽  
Breaking Strength ◽  
Sodium Succinate ◽  
Treated Group ◽  
Common Type ◽  
Bone Formation Marker ◽  
Sprague Dawley ◽  
Oral Gavage ◽  
Methylprednisolone Sodium Succinate ◽  
Sprague Dawley Rats

Glucocorticoid-induced osteoporosis (GIO) is the most common type of secondary osteoporosis. The aim of this study was to compare the efficacy of quercetin, a plant-derived flavonoid, with alendronate in the prevention of GIO. Fifty-six Sprague–Dawley rats were randomly distributed among 7 groups (8 rats per group) and treated for 6 weeks with one of the following: (i) normal saline; (ii) 40 mg methylprednisolone sodium succinate (MP)/kg body mass; (iii) MP + 40 μg alendronate/kg; (iv) MP + 50 mg quercetin/kg; (v) MP + 40 μg alendronate/kg + 50 mg quercetin/kg; (vi) MP + 150 mg quercetin/kg; and (vii) MP + 40 μg alendronate/kg + 150 mg quercetin/kg. MP and alendronate were injected subcutaneously and quercetin was administered by oral gavage 3 days a week. At the end of the study, femur breaking strength was significantly decreased as a consequence of MP injection. This decrease was completely compensated for in groups receiving 50 mg quercetin/kg plus alendronate, and 150 mg quercetin/kg with or without alendronate. Quercetin noticeably elevated osteocalcin as a bone formation marker, while alendronate did not show such an effect. In addition, administration of 150 mg quercetin/kg increased femoral trabecular and cortical thickness by 36% and 22%, respectively, compared with the MP-treated group. These data suggest that 150 mg quercetin/kg, alone or in combination with alendronate, can completely prevent GIO through its bone formation stimulatory effect.

scholarly journals Effect of denosumab on bone formation marker P1NP

2017 ◽  
Vol 3 (3) ◽  
pp. S34
Author(s):  
Hitoshi Tanigawa ◽  
Y. Imoto ◽  
S. Nishiwaki ◽  
Y. Tamagawa ◽  
S. Imai
Keyword(s):  
Bone Formation ◽  
Bone Formation Marker

scholarly journals Impact of Artistic Gymnastics on Bone Formation Marker, Density and Geometry in Female Adolescents: ABCD-Growth Study

2019 ◽  
Vol 26 (2) ◽  
pp. 75 ◽  
Author(s):  
Isabella Neto Exupério ◽  
Ricardo Ribeiro Agostinete ◽  
André Oliveira Werneck ◽  
Santiago Maillane-Vanegas ◽  
Rafael Luiz-de-Marco ◽  
...  
Keyword(s):  
Bone Formation ◽  
Female Adolescents ◽  
Marker Density ◽  
Bone Formation Marker ◽  
Growth Study

scholarly journals Rapid suppression of bone formation marker in response to sleep restriction and circadian disruption in men

2019 ◽  
Vol 30 (12) ◽  
pp. 2485-2493 ◽  
Author(s):  
C.M. Swanson ◽  
W.M. Kohrt ◽  
P. Wolfe ◽  
K.P. Wright ◽  
S.A. Shea ◽  
...  
Keyword(s):  
Bone Formation ◽  
Circadian Disruption ◽  
Sleep Restriction ◽  
Bone Formation Marker

scholarly journals Interleukin-6 May Not Affect Bone Resorption Marker CTX or Bone Formation Marker P1NP in Humans

2020 ◽  
Vol 4 (9) ◽  
Author(s):  
Louise L Lehrskov ◽  
Sasha Kjeldsen ◽  
Mark P Lyngbæk ◽  
Regitse Højgaard Chirstensen ◽  
Anne-Sophie Wedell-Neergaard ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Crossover Study ◽  
Bone Remodeling ◽  
Interleukin 6 ◽  
Plasma Concentrations ◽  
Bone Resorption Marker ◽  
Healthy Individuals ◽  
Bone Formation Marker ◽  
Double Blinded

Abstract Context Interleukin 6 (IL-6) contributes to bone remodeling in preclinical studies. Clinical trials investigating the role of IL-6 in bone remodeling are limited. Objective To investigate if IL-6 regulates bone remodeling in humans. Design Plasma concentrations of the bone resorption marker carboxy-terminal type I collagen crosslinks (CTX) and of the bone formation marker procollagen type 1 N-terminal propeptide (P1NP) were measured during a mixed-meal tolerance test (MMTT) in 3 placebo-controlled human studies. Participants Five healthy individuals participated in study 1; 52 obese individuals, in study 2; and 10 healthy individuals, in study 3. Interventions Study 1 was a single-blinded crossover study consisting of a 1-h infusion of saline (placebo) or the IL-6 receptor antibody tocilizumab followed by an exercise bout. Study 2 was a randomized, double-blinded 12-week exercise training intervention study. Participants received infusions of saline or tocilizumab. Study 3 was a randomized, double-blinded, crossover study consisting of 30 min infusion of saline or IL-6. Main outcomes measures Effect of IL-6 on CTX levels. Results CTX was significantly (P < 0.01) decreased during MMTTs in all 3 studies. Treatment with tocilizumab did not affect exercise or meal induced changes in plasma CTX or P1NP concentrations acutely (study 1) or after a 12-week treatment period (study 2). Exogenous IL-6 had no effect on CTX or P1NP plasma concentrations (study 3). Conclusions IL-6 may not regulate bone remodeling in humans.

Weekly sprinting of juvenile animals increases bone strength and size as well as bone formation marker concentration

2019 ◽  
Vol 76 ◽  
pp. 51
Author(s):  
A. Logan ◽  
B. Nielsen ◽  
C. Robison ◽  
J. Manfredi ◽  
H. Schott ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Strength ◽  
Bone Formation Marker

The bone formation marker N-terminal propeptide of type I collagen is also a marker for fibrogenesis in aged bile duct ligated rats

Bone ◽  
2009 ◽  
Vol 44 ◽  
pp. S373
Author(s):  
S.S. Veidal ◽  
D.J. Leeming⁎ ◽  
A. Bay-Jensen ◽  
T. Segovia-Silvestre ◽  
G. Tougas ◽  
...  
Keyword(s):  
Bile Duct ◽  
Bone Formation ◽  
Type I Collagen ◽  
Type I ◽  
Bone Formation Marker

scholarly journals Biochemical Markers of Bone Turnover in Rheumatoid Arthritis Patients Treated with Glucocorticoids

2019 ◽  
Vol 70 (2) ◽  
pp. 623-626
Author(s):  
Luana Andreea Macovei ◽  
Alexandra Burlui ◽  
Elena Rezus
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Biochemical Markers ◽  
Corticosteroid Treatment ◽  
Control Group ◽  
Bone Resorption Marker ◽  
Bone Formation Marker ◽  
Markers Of Bone Turnover

Osteocalcin and deoxypyridinoline levels were measured in 55 RA patients during and after glucocorticoid therapy with prednisone, methylprednisolone and cortisone. A decrease of 27% of the bone resorption marker deoxypyridinoline (from 10.13 to 7.4) and an increase of 23% of the bone formation marker osteocalcin (from 16.3 to 20.1) were also clinically confirmed by the presence of osteoporosis in 74% of patients receiving corticosteroid treatment as compared with only 31% in the control group.

scholarly journals Effect of denosumab on bone formation marker P1NP

2018 ◽  
Vol 26 ◽  
pp. S89
Author(s):  
H. Tanigawa ◽  
T. Maeda ◽  
K. Kumagai ◽  
S. Imai
Keyword(s):  
Bone Formation ◽  
Bone Formation Marker
Sign in / Sign up

Export Citation Format

Share Document